Compare STRIDES PHARMA SCIENCE with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs IPCA LABS - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE IPCA LABS STRIDES PHARMA SCIENCE/
IPCA LABS
 
P/E (TTM) x 14.1 22.9 61.4% View Chart
P/BV x 0.8 4.4 18.7% View Chart
Dividend Yield % 0.6 0.1 553.2%  

Financials

 STRIDES PHARMA SCIENCE   IPCA LABS
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
IPCA LABS
Mar-18
STRIDES PHARMA SCIENCE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,147695 164.9%   
Low Rs642400 160.5%   
Sales per share (Unadj.) Rs317.2260.2 121.9%  
Earnings per share (Unadj.) Rs7.819.0 41.3%  
Cash flow per share (Unadj.) Rs25.133.1 75.8%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.20.2 122.5%  
Book value per share (Unadj.) Rs274.3213.0 128.7%  
Shares outstanding (eoy) m89.50126.20 70.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.1 133.9%   
Avg P/E ratio x114.028.9 395.0%  
P/CF ratio (eoy) x35.716.6 215.5%  
Price / Book Value ratio x3.32.6 126.9%  
Dividend payout %25.55.3 483.7%   
Avg Mkt Cap Rs m80,05869,120 115.8%   
No. of employees `0002.513.3 18.9%   
Total wages/salary Rs m4,3417,359 59.0%   
Avg. sales/employee Rs Th11,325.82,477.4 457.2%   
Avg. wages/employee Rs Th1,731.4555.2 311.8%   
Avg. net profit/employee Rs Th280.1180.6 155.0%   
INCOME DATA
Net Sales Rs m28,39432,836 86.5%  
Other income Rs m941418 225.0%   
Total revenues Rs m29,33433,254 88.2%   
Gross profit Rs m3,9654,505 88.0%  
Depreciation Rs m1,5401,777 86.7%   
Interest Rs m1,962240 817.0%   
Profit before tax Rs m1,4032,905 48.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97511 19.0%   
Profit after tax Rs m7022,394 29.3%  
Gross profit margin %14.013.7 101.8%  
Effective tax rate %6.917.6 39.4%   
Net profit margin %2.57.3 33.9%  
BALANCE SHEET DATA
Current assets Rs m24,83619,455 127.7%   
Current liabilities Rs m18,99310,076 188.5%   
Net working cap to sales %20.628.6 72.0%  
Current ratio x1.31.9 67.7%  
Inventory Days Days7198 72.5%  
Debtors Days Days11367 169.4%  
Net fixed assets Rs m34,28920,260 169.2%   
Share capital Rs m895252 354.6%   
"Free" reserves Rs m23,65126,633 88.8%   
Net worth Rs m24,54626,886 91.3%   
Long term debt Rs m15,5132,340 662.9%   
Total assets Rs m65,43741,173 158.9%  
Interest coverage x1.713.1 13.1%   
Debt to equity ratio x0.60.1 726.1%  
Sales to assets ratio x0.40.8 54.4%   
Return on assets %4.16.4 63.6%  
Return on equity %2.98.9 32.1%  
Return on capital %6.910.8 64.1%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m15,69715,642 100.4%   
Fx outflow Rs m7354,884 15.1%   
Net fx Rs m14,96210,759 139.1%   
CASH FLOW
From Operations Rs m1,8713,411 54.8%  
From Investments Rs m5,826-1,354 -430.3%  
From Financial Activity Rs m-10,157-1,304 778.8%  
Net Cashflow Rs m-2,615753 -347.2%  

Share Holding

Indian Promoters % 27.7 45.9 60.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 11.4 331.6%  
FIIs % 8.6 25.3 34.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 17.4 148.9%  
Shareholders   56,241 36,892 152.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Higher; HCL Technologies & SBI Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a mixed note with stocks in the consumer durables sector.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 23, 2019 01:17 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS